A high-level working group will explore legal pathways to market for certain CBD products, according to the US FDA – which also revealed it had sent warning letters to three companies it accused of “unfounded claims”
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.